Evidence map›Paper›PMID 29058817›Full record

Trial reportCancer science2018

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.

Takashi Kumagai, Chiaki Nakaseko, Kaichi Nishiwaki, Chikashi Yoshida, Kazuteru Ohashi, Naoki Takezako, Hina Takano, Yasuji Kouzai, Tadashi Murase, Kosei Matsue and 6 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Observational
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Treatment-Free Remission in Chronic Myeloid Leukemia.Journal of clinical medicine · 2024
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Observational
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Takashi KumagaiDepartment of Hematology, Ome Municipal General Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0001-6850-4545
Chiaki NakasekoDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Kaichi NishiwakiDivision of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Kashiwa Hospital, Chiba, Japan.
Chikashi YoshidaDepartment of Hematology, National Hospital Organization, Mito Medical Center, Higashiibarakigun, Japan.
Kazuteru OhashiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Naoki TakezakoDepartment of Hematology, National Hospital Organization Disaster Medical Center, Tachikawa, Japan.
Hina TakanoDepartment of Hematology, Musashino Red Cross Hospital, Musashino, Japan.
Yasuji KouzaiDepartment of Hematology, Tokyo Metropolitan Tama Synthesis Medical Center, Tokyo, Japan.
Tadashi MuraseDepartment of Laboratory Medicine, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan.
Kosei MatsueDivision of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.ORCID http://orcid.org/0000-0002-8669-9865
Satoshi MoritaDepartment of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Junichi SakamotoTokai Central Hospital, Kakamigahara, Japan.
Hisashi WakitaDivision of Hematology and Oncology, Japanese Red Cross Society, Narita Red Cross Hospital, Narita, Japan.
Hisashi SakamakiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Koiti InokuchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Kanto CML and Shimousa Hematology Study Groups

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosine kinase inhibitors (TKI) improve the prognosis of patients with chronic myelogenous leukemia (CML) by inducing substantial deep molecular responses (DMR); some patients have successfully discontinued TKI therapy after maintaining DMR for ≥1 year. In this cessation study, we investigated the optimal conditions for dasatinib discontinuation in patients who maintained DMR for ≥2 years. This study included 54 patients with CML who were enrolled in a D-STOP multicenter prospective trial, had achieved DMR, and had discontinued dasatinib after 2-year consolidation. Peripheral lymphocyte profiles were analyzed by flow cytometry. The estimated 12-month treatment-free survival (TFS) was 62.9% (95% confidence interval: 48.5%-74.2%). During dasatinib consolidation, the percentage of total lymphocytes and numbers of CD3

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsConsolidation ChemotherapyDasatinibDisease-Free SurvivalFemaleFlow CytometryFusion Proteins, bcr-ablHumansKiller Cells, NaturalLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedProspective StudiesAntineoplastic AgentsBCR-ABL1 fusion protein, humanDasatinibFusion Proteins, bcr-ablchronic myelogenous leukemiadasatinibnatural killerstoptyrosine kinase inhibitors

Identifiers

PMID29058817
PMCPMC5765311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.